Plasmodium falciparum merozoite surface antigen-specific cytophilic IgG and control of malaria infection in a Beninese birth cohort (scientific article published on 11 June 2019)

Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites

Q28541281

A phase 1 trial of MSP2-C1, a blood-stage malaria vaccine containing 2 isoforms of MSP2 formulated with Montanide® ISA 720

Q28744696

The quantity and quality of African children's IgG responses to merozoite surface antigens reflect protection against Plasmodium falciparum malaria

Q33512926

Acquisition of antibody isotypes against Plasmodium falciparum blood stage antigens in a birth cohort

Q33621604

Levels of antibody to conserved parts of Plasmodium falciparum merozoite surface protein 1 in Ghanaian children are not associated with protection from clinical malaria.

Q33866742

Association of antibody responses to the conserved Plasmodium falciparum merozoite surface protein 5 with protection against clinical malaria

Q33927906

Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial

Q34043843

Modeling the influence of local environmental factors on malaria transmission in Benin and its implications for cohort study

Q34124974

High-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen 1 and induction of antibodies that inhibit erythrocyte invasion

Q34129066

Plasmodium falciparum malaria in children aged 0-2 years: the role of foetal haemoglobin and maternal antibodies to two asexual malaria vaccine candidates (MSP3 and GLURP).

Q34215916

Assessment of the neutrophilic antibody-dependent respiratory burst (ADRB) response to Plasmodium falciparum

Q34484078

Acquisition of antibodies against Plasmodium falciparum merozoites and malaria immunity in young children and the influence of age, force of infection, and magnitude of response

Q34955461

Target antigens of purified human immunoglobulins which inhibit growth of Plasmodium falciparum in vitro

Q59065277

Targets of complement-fixing antibodies in protective immunity against malaria in children

Q61799382

Immune effector mechanisms in malaria

Q82383609

Human antibodies fix complement to inhibit Plasmodium falciparum invasion of erythrocytes and are associated with protection against malaria

Q35213495

Relationship between maternally derived anti-Plasmodium falciparum antibodies and risk of infection and disease in infants living in an area of Liberia, west Africa, in which malaria is highly endemic.

Q35444728

First malaria infections in a cohort of infants in Benin: biological, environmental and genetic determinants. Description of the study site, population methods and preliminary results

Q35819766

Antibody-dependent cellular inhibition is associated with reduced risk against Febrile malaria in a longitudinal cohort study involving Ghanaian children

Q36051947

Malaria--a neglected disease?

Q36127074

Plasmodium falciparum Protein Microarray Antibody Profiles Correlate With Protection From Symptomatic Malaria in Kenya

Q36148976

Antibodies to Plasmodium falciparum merozoite surface protein-1p19 malaria vaccine candidate induce antibody-dependent respiratory burst in human neutrophils

Q36169093

Dynamics and role of antibodies to Plasmodium falciparum merozoite antigens in children living in two settings with differing malaria transmission intensity

Q36381444

Humoral responses to plasmodium falciparum blood-stage antigens and association with incidence of clinical malaria in children living in an area of seasonal malaria transmission in Burkina Faso, West Africa.

Q36421572

Contrasting Patterns of Serologic and Functional Antibody Dynamics to Plasmodium falciparum Antigens in a Kenyan Birth Cohort

Q36555103

Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria

Q36594057

Targets and Mechanisms Associated with Protection from Severe Plasmodium falciparum Malaria in Kenyan Children

Q36728063

Cohort study of the association of antibody levels to AMA1, MSP119, MSP3 and GLURP with protection from clinical malaria in Ghanaian children

Q36862490

Identification and prioritization of merozoite antigens as targets of protective human immunity to Plasmodium falciparum malaria for vaccine and biomarker development

Q36984161

A threshold concentration of anti-merozoite antibodies is required for protection from clinical episodes of malaria

Q37148056

Acquisition of natural humoral immunity to P. falciparum in early life in Benin: impact of clinical, environmental and host factors

Q37285306

Antibodies to the N-terminal block 2 of plasmodium falciparum merozoite surface protein 1 are associated with protection against clinical malaria

Q37582802

Recombinant protein vaccines against the asexual blood stages of Plasmodium falciparum

Q37671494

The effect of human immune IgG on the in vitro development of Plasmodium falciparum

Q38893586

A principal target of human immunity to malaria identified by molecular population genetic and immunological analyses

Q38952180

High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya

Q39362550

Plasmodium falciparum infection and age influence parasite growth inhibition mediated by IgG in Beninese infants

Q39900145

Merozoite Surface Protein 1 from Plasmodium falciparum Is a Major Target of Opsonizing Antibodies in Individuals with Acquired Immunity against Malaria

Q40055186

A novel antibody-dependent cellular cytotoxicity mechanism involved in defense against malaria requires costimulation of monocytes FcgammaRII and FcgammaRIII.

Q40168745

Soluble and glyco-lipid modified baculovirus Plasmodium falciparum C-terminal merozoite surface protein 1, two forms of a leading malaria vaccine candidate

Q40260804

A longitudinal investigation of IgG and IgM antibody responses to the merozoite surface protein-1 19-kiloDalton domain of Plasmodium falciparum in pregnant women and infants: associations with febrile illness, parasitemia, and anemia.

Q40640896

Naturally acquired cellular and humoral immune responses to the major merozoite surface antigen (PfMSP1) of Plasmodium falciparum are associated with reduced malaria morbidity.

Q40734085

Plasmodium falciparum strain-specific human antibody inhibits merozoite invasion of erythrocytes

Q41919648

Variations in the quality of malaria-specific antibodies with transmission intensity in a seasonal malaria transmission area of Northern Ghana

Q41994486

Genetic characterization of Plasmodium falciparum allelic variants infecting mothers at delivery and their children during their first plasmodial infections.

Q42251664

Pattern of immunoglobulin isotype response to Plasmodium falciparum blood-stage antigens in individuals living in a holoendemic area of Senegal (Dielmo, west Africa).

Q44710649

Assessment of the role of the humoral response to Plasmodium falciparum MSP2 compared to RESA and SPf66 in protecting Papua New Guinean children from clinical malaria

Q46227346

Detection of Malaria Parasites After Treatment in Travelers: A 12-months Longitudinal Study and Statistical Modelling Analysis

Q46280172

Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1.

Q46334562

IgG responses to candidate malaria vaccine antigens in the urban area of Dakar (Senegal): evolution according to age and parasitemia in patients with mild symptoms

Q47912581

Antibody-Dependent Cell-Mediated Inhibition (ADCI) of Plasmodium falciparum: One- and Two-Step ADCI Assays

Q47931529

Antibodies to the conserved C-terminal domain of the Plasmodium falciparum merozoite surface protein 1 and to the merozoite extract and their relationship with in vitro inhibitory antibodies and protection against clinical malaria in a Senegalese vi

Q48000659

Identifying Immune Correlates of Protection Against Plasmodium falciparum Through a Novel Approach to Account for Heterogeneity in Malaria Exposure

Q50062994

A mixture model with detection limits for regression analyses of antibody response to vaccine.

Q51038295

P433

issue

P921

main subject

malaria

Q12156

Plasmodium falciparum